SEC Comment Letter for Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040) (PHIO) — Apr 5, 2018
Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040)
Date: April 5, 2018 · CIK: 0001533040 · Accession: 0000000000-18-010382
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-224031
Letter
April 5, 2018 Geert Cauwenbergh President, Chief Executive Officer and acting Chief Financial Officer RXi Pharmaceuticals Corporation 257 Simarano Drive, Suite 101 Marlborough, MA 01752 Re:RXi Pharmaceuticals Corporation Registration Statement on Form S-3 Filed March 29, 2018 File No. 333-224031 Dear Dr. Cauwenbergh: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Ryan A. Murr, Esq.
Show Raw Text
April 5, 2018
Geert Cauwenbergh
President, Chief Executive Officer and acting Chief Financial Officer
RXi Pharmaceuticals Corporation
257 Simarano Drive, Suite 101
Marlborough, MA 01752
Re:RXi Pharmaceuticals Corporation
Registration Statement on Form S-3
Filed March 29, 2018
File No. 333-224031
Dear Dr. Cauwenbergh:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Ryan A. Murr, Esq.